Program
Methylprednisolone
Also written as “methylprednisolone”, “Vasopressin; Methylprednisolone; Hydrocortisone” and “Methylprednisolone/prednisolone”.
Its studies are mostly in Multiple Sclerosis, Relapsing-Remitting · Multiple Myeloma · Diabetes Insipidus · Myopathies, Structural, Congenital · Gaucher Disease, led by 9 companies.
Drug pageMethylprednisolone: every studyMany companies study it; this page follows only the 16 they lead. All 405 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogenits history only | 40 open or running | phase 4since May 27, 2005 | May 27, 2005 | none ahead |
| Pfizerits history only | 40 open or running | phase 1since Dec 13, 2010 | Dec 13, 2010 | none ahead |
| Oncotherapeuticsits history only | 22 open or running | phase 1since Nov 7, 2023 | Nov 7, 2023 | Apr 1, 2027phase 1 · NCT06225310 |
| Amsterdam Molecular Therapeuticsits history only | 10 open or running | phase 3since Apr 30, 2009 | Apr 30, 2009 | none ahead |
| Astellas Pharmaits history only | 11 open or running | phase 2since Jun 30, 2025 | Jun 30, 2025 | Oct 31, 2027phase 2 · NCT07052929 |
| Bristol-Myers Squibbits history only | 10 open or running | phase 2since May 4, 2016 | May 4, 2016 | none ahead |
| Chong Kun Dang Pharmaceutical | 10 open or running | phase 4since Jan 3, 2019 | Jan 3, 2019 | none ahead |
| Eli Lillyits history only | 11 open or running | phase 2since May 11, 2020 | May 11, 2020 | Feb 2027phase 2 · NCT04411654 |
| Sun Pharmaceutical Industriesits history only | 10 open or running | phase 2since Oct 31, 2016 | Oct 31, 2016 | none ahead |
Also a collaborator on its studies: Incyte, Elan Pharmaceuticals and The Clinical Trial.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Chong Kun Dang Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 3, 2019First study: phase 4 study in Kidney TransplantFirst studyNCT03794492 · 169 enrolled · Korea, Republic of
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
The one study Chong Kun Dang Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03794492Kidney Transplant · Korea, Republic of | 4 | Completed | Jul 22, 2022 | 169 |
How it is read
Names in the registry
- “methylprednisolone”, 16 entries
- “Methylprednisolone”, 7 entries
- “Vasopressin; Methylprednisolone; Hydrocortisone”, 1 entry
- “Methylprednisolone/prednisolone”, 1 entry
- “abiraterone acetate with Methylprednisolone”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, Relapsing-Remitting, 4 studies
- Multiple Myeloma, 2 studies
- Diabetes Insipidus, 1 study
- Myopathies, Structural, Congenital, 1 study
- Gaucher Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.